Bronchitis therapeutic pipeline is likely to experience a positive trend in future due to decreasing quality of the air and increasing smoking. Prevalence of bronchitis is increasing due to environmental factors, genetic factors, infections, industrial pollution, less physical activity and smoking. Some of the main factors driving the pipeline analysis for bronchitis include increasing treatment cost, increasing high rate of hospitalizations due to chronic bronchitis, increasing alpha-1-antitrypsin (AAt) deficiency, low market penetration of effective drugs and increasing health awareness. According to Centers for Disease Control and Prevention, around 9.3 million people were diagnosed with chronic bronchitis in U.S in 2015. Chronic bronchitis is the third leading cause of deaths in the U.S. According to the data by American Lung Association (ALA) the risk of chronic bronchitis increases with age. Among people over 65 years old, the rate is 64.2 per 1,000 persons. For the people aged between 18 to 44year, the rate was 28.6 per 1,000 persons. The rate at which the disease affects the females is almost double, as compared to males.
Bronchitis is a condition which involves inflammation of bronchial tubes due to infection. This results in much more mucus with cough. There are two types of bronchitis, acute bronchitis and chronic bronchitis. Acute bronchitis is usually more common form of bronchitis which does not cause much problems. It includes common cold or flu which lasts for few days or weeks. Chronic bronchitis can also result in chronic obstructive pulmonary disease (COPD). Bronchitis is caused by either viruses, bacteria, or other irritant particles such as dust, fumes, air pollution and others, same as in the case of cold or flu. The production of more mucus results in problem in breathing with smaller opening for air to flow. The symptoms of bronchitis include fever, chest congestion, breath shortening, body aches, wheezing sound while breathing, headaches, cough with mucus and runny nose. Bronchitis is diagnosed by lung function test, chest X-ray, blood test, mucus testing and measuring oxygen levels in blood. The disease can be treated by using inhalers, bronchodilators, oxygen therapy, anti-inflammatory medicines, glucocorticoid steroids, antibiotics and over-the-counter pain relievers. Some of the home remedies can also be used to treat bronchitis like steam and drinking more water.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/bronchitis-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of bronchitis therapeutics include EmeraMed Ltd., Vertex Pharmaceuticals Incorporated, SolAeroMed Inc., Novartis AG, AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Dompé Farmaceutici S.p.A, Invion Limited, Mucosis B.V.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)